ResearchSafe

Ibogaine (Ibogaine (from Tabernanthe iboga))

Category: Psychedelics. Status: Schedule I (research compound).

A plant-derived psychedelic studied mainly for interrupting opioid and other substance addictions. A single session is reported to sharply reduce withdrawal and cravings, but it carries real heart-rhythm risks that demand medical monitoring.

How it works

Acts on multiple systems at once, including serotonin and opioid receptors, NMDA receptors and nicotinic receptors. Its active metabolite noribogaine is thought to drive much of the lasting anti-addiction effect.

Key facts

  • Molecular weight: 310.43 g/mol
  • Half-life: ~4-7 hours (ibogaine); noribogaine much longer
  • Bioavailability: Oral
  • Storage: Research/clinical settings only.

Dosing overview

  • Typical dose: Weight-based, given in specialized clinics
  • Frequency: Usually a single session
  • Duration: Acute effects last 8-24 hours
  • Route: Oral, under medical and cardiac monitoring

Protocol notes

  • Given in specialized clinics as a single large oral dose, almost always to interrupt opioid addiction.
  • The person is hooked up to heart monitoring because ibogaine can dangerously affect heart rhythm.
  • They lie down for a long (up to a day) dreamlike, waking-dream experience while staff watch vital signs.
  • It is never a casual or recreational drug; unmonitored use has caused deaths.

Reported benefits

  • Studied for opioid use disorder
  • Can reduce withdrawal symptoms quickly
  • May lower cravings after a single session
  • Investigated for traumatic brain injury (with magnesium) in veterans

Possible side effects

  • Dangerous heart-rhythm changes (QT prolongation)
  • Ataxia (loss of coordination)
  • Nausea and vomiting
  • Long, intense experience
  • Risk of death without cardiac monitoring

Research

  • Magnesium-Ibogaine therapy in veterans with traumatic brain injury (2024): Stanford study reported large reductions in PTSD, anxiety and depression and improved functioning after a single supervised treatment.
  • Ibogaine for opioid detoxification (observational) (2018): Reported reductions in opioid withdrawal and craving, while emphasizing cardiac safety concerns.

Community reviews of Ibogaine

Rated 4.3 out of 5 from 3 community reviews by ResearchSafe members.

  • reid664 rated it 4/5 - Strong reset, but the aftertaste was rough: I tried ibogaine after years of hard training, night shifts, and too much wear from firefighting. For me it felt like a hard reset, and the cravings stayed quieter for a while over about 10 weeks. The downside was the body load, I felt drained and a bit foggy for days after, quite shiok but not easy.
  • megan302 rated it 5/5 - skeptical at first, but it shook loose a lot: i went in pretty skeptical, honestly. as a retired firefighter on the west coast, i’ve seen enough hype to roll my eyes. after about 3 months, ibogaine seemed to quiet the obsessive edge i was carrying, and that surprised me. i still keep it in the “careful, serious” category.
  • coastal_paddles rated it 4/5 - Withdrawal felt quieter, fast: The biggest thing for me was how quickly the withdrawal noise got knocked down. I work sales in the Midwest, long days, lots of driving, and that rattled edge in my body eased up within my 3 weeks on it. The downside was the intensity, so I stayed cautious.

Compare Ibogaine

Community discussions about Ibogaine

Research and educational reference only. Not medical advice.